Today, Dr. Bai Chen, Founder and Chairman of MoMed Biotech, appeared as a guest in the special program "Rising National Brands" of CCTV's Credit China, which was officially broadcast today. In the program, Dr. Bai Chen engaged in an in-depth dialogue with renowned host Dong Qian, systematically sharing his cutting-edge explorations and practical experience in the field of AI-powered new drug research and development for the first time. As a premium interview program produced by a professional CCTV team with the mission of documenting national visual archives, Credit China focused on the scientific and technological innovation sector this time, presenting the development landscape of the frontier field of AI drug discovery to audiences through Dr. Bai Chen’s insightful sharing.

During the interview, Dr. Bai Chen not only deeply analyzed the key challenges and breakthrough pathways faced by AI technology in new drug development but also publicly unveiled MoMed Biotech’s self-developed novel drug design methodology and latest research achievements for the first time. Notably, Dr. Bai Chen and Ms. Dong Qian engaged in a fascinating intellectual exchange on the topic of "the contemporary mission of scientific and technological workers and the future development of AI."

Against the backdrop of rapid AI technological iteration, this CCTV exclusive interview not only showcases MoMed Biotech’s technical prowess in the AI drug discovery field but also demonstrates the company’s firm belief in driving pharmaceutical industry upgrading through technological innovation. The program has been broadcast during prime time on CCTV's Old Stories Channel and is simultaneously available on major online platforms such as ifeng.com, China.com, and Sohu.com.

Traditional drug development faces challenges such as high costs, long cycles, and low success rates, with AI initially hailed as a potential solution. However, most AI-driven pharmaceutical companies overlook the "multidimensional coupled mechanisms" of target proteins, leading to insufficient activity in designed molecules and low viability for drug development.

MoMed Biotech’s core breakthrough lies in integrating the computational biology methodology of Nobel Chemistry Prize laureate Prof. Arieh Warshel into AI models. For the first time, it incorporates kinetic information about the physical and chemical dynamics of protein functions—including dynamic data on transition-state structures and energy barriers—into model training. This enables AI not only to design molecular structures but also to predict how drugs interact with disease targets. By combining "high-dimensional data" with "mechanism-based research," this approach raises the ceiling of AI pharmaceutical models, significantly improving the activity and success rate of MoMed’s AI-designed molecules compared to industry averages.

Bai Chen’s decision to start a business surprised peers: giving up a stable university faculty position, provincial talent subsidies, and resolutely diving into the uncertain entrepreneurial path. Reflecting on his motivation, he stated: "While at the university, I watched the industry pour vast funds into 'wrong directions,' which deeply pained me—AI design without studying protein mechanisms is like a blind man feeling an elephant, a castle in the air. We must return to scientific fundamentals and use correct physical-chemical data to solve AI quality issues."

Driven by the obsession to "drive change through technology," he invited his mentor, Prof. Arieh Warshel, to serve as a co-founder and built a team from scratch, aiming to prove: "Correct data + AI can free AI-driven innovative drug development from 'mysticism'."

On the industry’s current state, Bai Chen bluntly noted: "When the industry experiences a capital downturn, it 反而 (instead) creates opportunities for those truly committed to progress." MoMed’s goal is clear: to advance its pipelines into clinical trials within 3-5 years and validate the feasibility of "mechanism-driven AI drug discovery." Speaking about AI’s future, Bai Chen affirmed: "AI will undoubtedly be applied across all industries. If there’s even a possibility that my decades of expertise can drive this field’s development, I will pursue it with unwavering passion." This dedication is the core driving force behind MoMed Biotech’s continuous breakthroughs in AI drug discovery.

As a disruptor in the industry, Bai Chen leads MoMed Biotech in blazing a new trail with "Nobel Prize-level technical accumulation and systematic innovation." As he once said: "The romance of science lies in turning 'impossibility' into 'possibility'."   We look forward to this technological breakthrough from the laboratory to industrialization, which is poised to unlock infinite possibilities for the AI drug discovery field.  Broadcast Link (CCTV's Old Stories Channel via Yangshipin):https://m.cctv5g.com/yctv/live?contId=5500074026&dataType=4&startTime=   Premiere Time:  Thursday, June 5, 2025  09:47 / 17:47 (China Standard Time)   Replay Times: Friday, June 6, 2025  06:47 / 13:47 / 21:47 (China Standard Time)  Column Link:Credit China* 20250605 Episode 2 | Bai Chen: Charting a New Direction for AI-Driven New Drug Research and Development with Technology